Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149871 (
deep vein thrombosis
)
12,364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CCR2 is required for monocyte recruitment in many inflammatory processes, as well as conferring Th1 lymphokine responses.
Deep vein thrombosis (DVT)
resolution represents a specific inflammatory response whereby the thrombus must be dissolved for restoration of blood flow. Using a stasis model of
DVT
in the mouse, we investigated the role of CCR2 on
DVT
resolution. Genetic deletion of CCR2 (CCR2-/-) was associated with larger thrombi at early and later time points, increased thrombus collagen, fewer thrombus monocytes (F4/80), and significantly impaired neovascularization. IL-2 and
IFN-gamma
were significantly reduced in early CCR2-/- thrombi, whereas MCP-1 was significantly increased, and Th2 lymphokines were unaffected. Supplementation of CCR2-/- mice with
IFN-gamma
normalized early thrombus resolution without increasing monocyte influx. Neither Ab depletion of
IFN-gamma
nor genetic deletion of
IFN-gamma
impaired early
DVT
resolution. Early fibrinolysis was not impaired in CCR2-/- mice, but a significant reduction in both matrix metalloproteinase (MMP)-2 and MMP-9 activity was observed. However, only MMP-9 activity was restored with administration of
IFN-gamma
. We conclude that an early CCR2-dependent Th1 lymphokine response predominates in normal
DVT
resolution, mediates this in part by MMP-9 activation, but is not solely dependent on
IFN-gamma
.
...
PMID:Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. 1692 Sep 80